UK markets open in 2 hours 15 minutes

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
79.86-0.20 (-0.25%)
At close: 1:02PM EST
Sign in to post a message.
  • j
    james
    $SLS conversation
    Direct Comp for one indication of $SLS primary asset: 9.5 months of survival ='s $1.55B / $BMY $MRK $SLS proved 21 months of OS only trades for $25M?
    https://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
    compare for yourself
    SLS drug data from their website " The Company previously reported initial data from the Phase 1/2 study of GPS in AML patients in CR2 at a median follow-up of 19.3 months, showing median OS in GPS-treated patients of 16.3 months vs. 5.4 months in a patient cohort contemporaneously treated with best standard therapy (p = 0.0175). The final analysis, at a median follow-up of 30.8 months, now shows a median OS of 21 months in the GPS-treated patient cohort.
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was to go ahead.
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was to go ahead.
    www.fiercebiotech.com
  • E
    Ez$
    $SLS conversation
    The real question is who will be buying this and is there a bidding war?
    https://www.freethink.com/articles/skin-cancer-vaccine
    "These positive results are significant not only for improving cancer vaccines, but also potentially for application to other vaccine platforms,"
    $BMY Combination trials for Ovarian Cancer and Mesothelioma -Meso data now tabulated and due for release.
    $Mrk Combination Trials for 5 Indications $ROCHE Combo P2B proved a 80% Reduction in TNBC Recurrence
  • a
    anesth2go
    Is MRK working on a pill vaccine for COVID? Do not see reference to this anywhere.
  • V
    Visonary
    $ACRX conversation
    "AcelRx thinks this drug can eventually generate more than $1 billion in annual sales." Why many think either $PFE or $MRK could make a run for ACRX, with ACRX's Orange Book patents into 2031, w/ more pending!
    Pfizer, Merck drop after Wall Street downgrades on ‘patent cliff’ and competition
    PUBLISHED WED, JAN 23 2019
    - UBS slashes Pfizer’s rating to neutral from buy, citing the so-called “patent cliff” in the coming years that would greatly offset the revenue growth.
    - BMO downgrades Merck to market perform from outperform, saying Wall Street’s expectations for the drugmaker are too high given its over-dependence on the drug Keytruda.

    Shares of Pfizer and Merck fell on Wednesday after Wall Street analysts downgraded the drugmakers on increased competition and the pending loss of patent protection.
  • g
    greg
    Nps awarded prime spotlight discussion at SABCs - this data is tabulated and circulating IMO - also June 9 the ceo essentially said there was a bidding war for Nps and something would be happening after the National Cancer Institute DCIS Trial Data came in ... - $roche interested $BMY and $MRK sniffing around the Primary asset Gps - keytruda and opdivo combo data has been spectacular
  • T
    The Chewdog
    This CEO needs to respectfully retire. Who else is at fault for having a product mix where 66% must be administered by a physician? Who painted us into this corner? I bet he never even knew, or thought about it.
    That’s his problem he’s been running the company with one hand on the wheel one hand in politics way too long. If you disagree please support your position with FACTS
  • D
    DueDiligenceSmart
    AcelRx Pharmaceuticals, Inc.
    $PFE $MRK or $ZBH bidding war for ACRX... ACRX jumped 10% on Volume... news leak!
  • A
    Anonymous
    Shock for a report. MRK got hardest hit by covid. Lost 3% sale. Surviving? Cost cutting ahead? Shareholders will cry. What a Thanksgiving and Christmas if holding this stock.
  • P
    Peter
    Don’t suppose anyone knows when this might start to perform 🧐. This is like pulling teeth. Must admit I’m disappointed. I researched MRK. Looked a good investment & in the last three months look what’s happening. I really don’t mind the long journey here. Just some positive ups would be good.🥴
  • W
    William
    News of Berkshire Hathaway's purchase of MRK may well give be the catalyst for it breaking out of this consolidation phase.
  • M
    Maverick
    Great company but its stock is a chronic laggard. Hold for better times.
  • A
    Anonymous
    Pharmaceutical titan Merck (MRK) agreed to purchase VelosBio, a biopharmaceutical company focusing on cancer, for $2.75 billion in cash.
    The lead investigational candidate at VelosBio, San Diego, is VLS-101, an antibody-drug conjugate currently being evaluated in a Phase 1 and Phase 2 clinical trial to treat patients with hematologic malignancies and solid tumors.
  • D
    Doggoneit
    why is this stock tanking? the market is up today!!
  • T
    The Chewdog
    Read the report from Reuters this am, MRK buying OncoImune for a COVID treatment candidate.
    A little late to the game, but focusing on treatment rather than prevention MAY be a step in the right direction. FWIW the writer incorrectly claims the oral corticosteroid dexamethasone “dex” is MRK property. This is incorrect dex was off patent decades ago and can/is manufactured by any company in the world.
  • D
    Daniel
    Berkshire's 22million share plus and dividend raised by 4cents a quarter show confidence in the coming quarters and the company split. Looking ahead!
  • j
    james
    $SLS conversation
    9.5 months of survival ='s $1.55B / $BMY $MRK $SLS proved 21 months of OS only trades for $25M?
    https://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
    compare for yourself
    SLS drug data from their website " The Company previously reported initial data from the Phase 1/2 study of GPS in AML patients in CR2 at a median follow-up of 19.3 months, showing median OS in GPS-treated patients of 16.3 months vs. 5.4 months in a patient cohort contemporaneously treated with best standard therapy (p = 0.0175). The final analysis, at a median follow-up of 30.8 months, now shows a median OS of 21 months in the GPS-treated patient cohort.
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was to go ahead.
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was to go ahead.
    www.fiercebiotech.com
  • A
    Anonymous
    MRK missed covid opportunity. Nothing exciting even after the recent tiny acquisition. Dead money.
  • l
    lily
    Mrk is big vaccine maker, will mrk be moderna covid-19 maker?
  • T
    Travis
    Warren Buffet and Berkshire Hathaway purchased 22 million shares of Merck!!!
  • R
    Rod
    Did Berkshire purchase the shares on the open market, direct from company, or by other means?